Lovecek M, Neoral C, Klos D, Skalický P, Kysucan J, Vrba R, Melichar B, Svébisová H, Tozzi di Angelo I, Kliment M, Havlík R
I. Chirurgická klinika LF UP a FN Olomouc.
Rozhl Chir. 2010 Dec;89(12):731-9.
Surgical treatment plays a key role in the efforts to improve prognosis of patients with pancreatic cancer. The pancreatic cancer incidence rates are on increase and so does the number of patients undergoing potentially curative resection procedures. However, despite all diagnostic advancements and treatments adjusted to specific patient's needs, the outcomes are not satisfactory enough. The aim of the surgical procedure is to radically remove the tumor, including the regional lymph nodes, to promote early and uncomplicated healing and to facilitate early initiation of oncological treatment.
The aim of the study was to assess current potential of diagnostic and surgical treatment in pancreatic cancer when all currently available diagnostic methods are emloyed and to present the university clinic's outcomes. METHODS AND PATIENT GROUP: From 2006 to IX 2010, a total of 177 pancreatic resections and 123 right-sided pancreatoduodenectomies for malignant disorders were performed at the authors' clinic. 76 pancreatoduodenectomies were performed for ductal carcinoma of the pancreatic head. The study group included 51 males and 25 females, the mean age of 62.9 years. Based on the TNM classification (UICC), 11% of the subjects presented with stage I, 78% with stage II and 3% with stage III diseases. The procedures radicality was the following: R0 in 59 subjects, R1 in 5 subjects while in 12 subjects, the radicality was undetected by the authors. Histopatological grading in this patient group was as follows: G1 in 20%, G2 in 34% and G3 in 46% of the subjects. Perineural invasion, invasion into lymphatic vessels or other vessels was not detected in 21 subjects (27.6%). The authors assessed complication rates based on the DeOliveira classification and survival rates in individual disease stages.
Complications occurred in 44.7% of the operated subjects. Serious complications requiring reintervention were reported in 13 subjects (17.1%), including reinterventions in general anesthesia in 10 subjects (13.1%). Two patients died: a 79-year old female died from multiorgan failure as a result of aspiration, and a 76-year old male died from multiorgan failure following completion of pancreatectomy due to pancreaticojejunal anastomosis insufficiency. The thirty- and sixty-day mortality rate was 2.6%, however, it was null over the past three years. The mean survival time was 17.1 months, with the median of 13.5 months. The patient group's overall 3-, 6-, 9-, 12, 15- and 18- month survival following radical resections was 95.6%, 90.3%, 76.3%, 62.7%, 52.3% and 45%, respectively. 82%, 52%, 35% and 35% of the operated stage I patients survived 1, 2, 3 and 4 years, respectively. The mean hospitalization duration was 16.8 days (10-45).
Although the procedures are extremely demanding, especially in the reconstruction phase, the outcomes have improved significantly due to ongoing experience, improvements in the surgical technique and in the complex postoperative care. At specialized clinics, the mortality rate has dropped below 5%, the morbidity rate below 40% and the postoperative dehiscence rates below 10%. During the past three years, the authors' clinic has reached null 30- and 60-day mortality rate following the pancreatic head resections, the complication rate following pancreaticoduodenal anastomosis is slightly above 5% (6.5%) and the morbidity rate is slightly above 40% (44.7%). The authors consider the procedure safe at their clinic and all indicated patients are expected to benefit from it.
手术治疗在改善胰腺癌患者预后的努力中起着关键作用。胰腺癌的发病率呈上升趋势,接受潜在根治性切除手术的患者数量也在增加。然而,尽管有所有的诊断进展以及根据特定患者需求调整的治疗方法,结果仍不尽人意。手术的目的是彻底切除肿瘤,包括区域淋巴结,促进早期且无并发症的愈合,并便于早期开始肿瘤治疗。
本研究的目的是评估在采用所有当前可用诊断方法时,胰腺癌诊断和手术治疗的当前潜力,并展示大学诊所的治疗结果。方法与患者群体:2006年至2010年9月,作者所在诊所共进行了177例胰腺切除术和123例针对恶性疾病的右侧胰十二指肠切除术。76例胰十二指肠切除术是针对胰头导管癌进行的。研究组包括51名男性和25名女性,平均年龄为62.9岁。根据TNM分类(国际抗癌联盟),11%的受试者为I期,78%为II期,3%为III期疾病。手术的根治程度如下:59例受试者为R0,5例为R1,12例受试者的根治程度作者未检测到。该患者群体的组织病理学分级如下:20%的受试者为G1,34%为G2,46%为G3。21名受试者(27.6%)未检测到神经周围侵犯、淋巴管或其他血管侵犯。作者根据DeOliveira分类评估了并发症发生率以及各个疾病阶段的生存率。
44.7%的手术受试者发生了并发症。13名受试者(17.1%)报告了需要再次干预的严重并发症,其中10名受试者(13.1%)在全身麻醉下进行了再次干预。两名患者死亡:一名79岁女性因误吸导致多器官功能衰竭死亡,一名76岁男性在胰十二指肠吻合口漏导致胰腺切除术后因多器官功能衰竭死亡。30天和60天死亡率为2.6%,然而在过去三年中为零。平均生存时间为17.1个月,中位数为13.5个月。根治性切除术后该患者群体总体3个月、6个月、9个月、12个月、15个月和18个月的生存率分别为95.6%、90.3%、76.3%、62.7%、52.3%和45%。I期手术患者分别有82%、52%、35%和35%存活了1年、2年、3年和4年。平均住院时间为16.8天(10 - 45天)。
尽管手术过程要求极高,尤其是在重建阶段,但由于经验的积累、手术技术的改进以及复杂的术后护理,结果有了显著改善。在专业诊所,死亡率已降至5%以下,发病率降至40%以下,术后切口裂开率降至10%以下。在过去三年中,作者所在诊所胰头切除术后30天和60天死亡率为零,胰十二指肠吻合术后并发症发生率略高于5%(6.5%),发病率略高于40%(44.7%)。作者认为该手术在其诊所是安全的,所有符合指征的患者都有望从中受益。